Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)
Status:
Active, not recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This study is determining whether the addition of cyclophosphamide to pomalidomide and
dexamethasone improves progression free survival in patients with relapsed refractory myeloma
(RRMM) compare to pomalidomide and dexamethasone alone. Patients will be randomised on a 1:1
basis to receive CPD or Pd. Treatment will be continued until disease progression or
unacceptable toxicity.